See the DrugPatentWatch profile for lurbinectedin

Based on the information available, there is no evidence to suggest that Lurbinectedin has been proven safe during pregnancy. Lurbinectedin is an antineoplastic agent, used to treat certain types of cancer, and it is currently not approved for use during pregnancy by regulatory agencies such as the US Food and Drug Administration (FDA) [1].

Animal studies have shown that Lurbinectedin can cause harm to the fetus, including embryo-fetal toxicity and teratogenic effects [2]. However, it is important to note that results from animal studies may not always predict the way humans will respond.

Additionally, a search on DrugPatentWatch.com, a website that provides information about drugs and their patents, does not yield any specific information regarding the use of Lurbinectedin during pregnancy [3].

In conclusion, based on the available information, Lurbinectedin has not been proven safe during pregnancy and its use during pregnancy is not recommended.

Sources:

1. US Food and Drug Administration. (2021). Zepzelca (lurbinectedin) prescribing information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214457s000lbl.pdf>
2. PharmaMar. (2021). Lurbinectedin (PM01183): Summary of product characteristics. <https://www.medicines.org.uk/emc/product/9356/smpc>
3. DrugPatentWatch. (2021). Lurbinectedin. <https://www.drugpatentwatch.com/drugs/lurbinectedin>